Preclinical biodistribution and dosimetry and human biodistribution comparing \(^{18}\)F-rhPSMA-7 and single isomer \(^{18}\)F-rhPSMA-7.3

Karina Knorr\(^1\)*, So Won Oh\(^1,2\), Markus Krönke\(^1,3\), Alexander Wurzer\(^4\), Calogero D’Alessandria\(^1\), Michael Herz\(^1\), Wolfgang Weber\(^1\), Hans-Jürgen Wester\(^4\), Matthias Eiber\(^1\), Nahid Yusufi\(^1\)† and Stephan Nekolla\(^1\)†

**Abstract**

**Background:** Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands such as \(^{18}\)F-rhPSMA-7 are a new class of theranostic agents in clinical development for prostate cancer. We compared preclinical dosimetry and human biodistribution of \(^{18}\)F-rhPSMA-7 with that of single diastereoisomer form, \(^{18}\)F-rhPSMA-7.3.

**Methods:** Preclinical dosimetry was performed with SCID-mice sacrificed at multiple timepoints (10–300 min) post-injection of \(25.6 \pm 3.6\) MBq \(^{18}\)F-rhPSMA-7 or \(28.5 \pm 4.8\) MBq \(^{18}\)F-rhPSMA-7.3 (\(n = 3–6\) mice per timepoint). Heart, lung, liver, spleen, pancreas, fat, stomach, small intestine, large intestine, kidney, muscle, bone, bladder, testicles, tail, and brain tissue were harvested, and urine and blood samples collected. Percentage of injected dose per gram was calculated. Absorbed doses were estimated with OLINDA/EXM 1.0. \(^{18}\)F-rhPSMA-7 (\(n = 47\)) and \(^{18}\)F-rhPSMA-7.3 (\(n = 33\)) PET/CT exams were used to estimate human biodistribution. Mean (range) injected activities were 324 (236–424) MBq versus 345 (235–420) MBq, and acquisition times were 84 (42–166) versus 76 (59–122) minutes for \(^{18}\)F-rhPSMA-7 versus \(^{18}\)F-rhPSMA-7.3, respectively. SUV \(_{\text{mean}}\) was determined for background (gluteal muscle), normal organs (salivary glands, blood pool, lung, liver, spleen, pancreas, duodenum, kidney, bladder, bone) and up to three representative tumour lesions. Qualitative analyses assessed image quality, non-specific blood pool activity, and background uptake in bone/marrow using 3/4-point scales.

**Results:** Preclinical dosimetry revealed that at 3.5 h and 1 h bladder voiding intervals, the extrapolated total effective doses were 26.6 and 12.2 µSv/MBq for \(^{18}\)F-rhPSMA-7 and 21.7 and 12.8 µSv/MBq for \(^{18}\)F-rhPSMA-7.3 respectively. Human biodistribution of both agents was typical of other PSMA-ligands and broadly similar to each other; SUV \(_{\text{mean}}\) were 16.9 versus 16.2 (parotid gland), 19.6 versus 19.9 (submandibular gland), 2.0 versus 1.9 (blood pool, \(p < 0.005\)), 0.7 versus 0.7 (lungs), 7.0 versus 7.3 (liver), 9.1 versus 8.4 (spleen), 32.4 versus 35.7 (kidney), 2.5 versus 2.8 (pancreas), 10.9 versus 11.0 (duodenum), 1.1 versus 1.3 (bone) and 4.6 versus 2.0 (bladder; \(p < 0.001\)) for \(^{18}\)F-rhPSMA-7 versus \(^{18}\)F-rhPSMA-7.3, respectively. Tumour SUV \(_{\text{mean}}\) was higher for \(^{18}\)F-rhPSMA-7.3 (32.5 ± 42.7, \(n = 63\) lesions) than for \(^{18}\)F-rhPSMA-7 (20.0 ± 20.2, \(n = 89\) lesions).

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background
Prostate-specific membrane antigen (PSMA) is overexpressed in nearly all primary prostate cancer [1], and PSMA expression further increases in de-differentiated, metastatic, or hormone-refractory disease [2, 3]. In recent years, PSMA targeting ligands have been investigated for molecular imaging and radioligand therapy of prostate cancer. Recent developments increasingly focus on 18F-based, rather than 68Ga-based PSMA ligands for imaging given the advantages of 18F-based agents in terms of availability, ease of production, and image resolution.

Several 18F-based PSMA ligands have been developed with different kinetic profiles. The kidneys and the urinary tracts are critical organs in the development of novel PSMA ligands as intense urinary retention may interfere with accurate evaluation of the prostate and adjacent area. 18F-labelled, urea-based inhibitors of PSMA such as 18F-DCFBC and 18F-DCFPyL demonstrated diagnostic capabilities in clinical trials [4, 5], but they still have shortcomings due to urinary excretion as their limitation to a diagnostic use. 18F-PSMA-1007 was developed aiming for similar structure, biodistribution and tumour uptake compared to PSMA-617 which is currently used for radioligand therapy. 18F-PSMA-1007 is predominantly excreted via the hepatobiliary tract and has very low urinary retention but its optimal imaging timepoint (120 min) is suboptimal for routine clinical practice [6].

Radiohybrid PSMA (rhPSMA) ligands are a new class of fully theranostic agents that allow fast 18F synthesis and labelling with radiometals. They are silicon-fluoride-acceptor (SiFA)–conjugated radiopharmaceuticals that are labeled by isotopic exchange. One example, 18F-rhPSMA-7, has been shown to have a biodistribution typical of other established PSMA ligands [7] and its clinical performance for imaging patients with prostate cancer has been reported previously [8, 9]. 18F-rhPSMA-7 is comprised of four diastereoisomers (rhPSMA-7.1, rhPSMA-7.2, rhPSMA-7.3 and rhPSMA-7.4), of which rhPSMA-7.3 exhibits the most promising targeting characteristics for clinical translation and has been selected for further development based on preclinical results [10].

Here, we analyzed the preclinical biodistribution and dosimetry of 18F-rhPSMA-7 and 18F-rhPSMA-7.3 at different timepoints after a single intravenous administration in mice. We further assessed biodistribution and image quality of clinical 18F-rhPSMA-7 and 18F-rhPSMA-7.3 PET scans in patients with histopathologically proven prostate cancer.

Methods
Synthesis of 18F-rhPSMA-7 and 18F-rhPSMA-7.3
The rhPSMA-7 and rhPSMA-7.3 peptide precursors were labelled with 18F and dissolved in phosphate buffered saline solution as previously described [11]. The 18F-labeling of rhPSMA-7 and rhPSMA-7.3 was performed in a fully automated, Good Manufacturing Practice-compliant procedure using a GRP™ synthesis module (Scintomics, Fürstenfeldbruck, Germany).

Preclinical biodistribution and dosimetry
Severe combined immunodeficiency (SCID) mice were supplied by Charles River Laboratories. (Freiburg, Germany). The preclinical evaluation study was performed in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval #55.2-1-54-2532-216-2015). Male mice (> 6 weeks old) were used for the study after reaching sexual maturation.

The biodistribution study was performed at multiple timepoints; 10, 20, 40, 60, 120 and 180 min post-injection of 18F-rhPSMA-7, and at 10, 60, 120, 180 and 300 min post-injection of 18F-rhPSMA-7.3. Based on initial experiments exhibiting prolonged renal uptake for 18F-rhPSMA-7.3, a late timepoint (300 min) was applied for the final experiments. At each timepoint, 3–6 mice were injected intravenously in the tail vein with a mean 25.6 ± 3.6 MBq of 18F-rhPSMA-7 and 28.5 ± 4.8 MBq of 18F-rhPSMA-7.3, respectively. For the biodistribution study, the mice were dissected and samples collected from urine, blood, heart, lung, spleen, pancreas, liver, stomach (emptied), small intestine (emptied), large intestine (emptied), kidneys, bladder, testis, fat, muscle (partial, femoral), femur, tail and brain. An automatic gamma counter (PerkinElmer-Wallac, Waltham, USA) was used to measure count rate and the percentages of the injected dose (%ID and %ID/g) were calculated.

Of note, to achieve a similar number of timepoints for both calculations, the 18F-rhPSMA-7 10 min and 20 min timepoints were interpolated to a 15 min timepoint. The time-integral of activity for the accumulation in the

Conclusions: Radiation dosimetry is favourable for both agents. Radiation exposure, assuming a 1 h voiding interval, is less than 5 mSv after injection of 370 MBq. 18F-rhPSMA-7.3 showed significantly lower bladder uptake, and a higher uptake trend in tumours compared with 18F-rhPSMA-7.

Keywords: 18F, Biodistribution, Dosimetry, PET/CT, PSMA, rhPSMA
investigated source organs (AUCs) were generated both with numerical integration and physical decay [12].

To extrapolate from preclinical data to human dosimetry, linear scaling of %ID from the mice by the ratio of the organ weights and total body weights of phantoms compared to humans was necessary [13]. Normal-organ radiation doses were estimated for the 70 kg standard adult anatomic model using time-dependent organ activity concentrations in %ID/g and total-body activities measured in the biodistribution studies in mice. Tissue activity concentrations in mice were converted to tissue fractional activities in the 70 kg standard adult using the relative fractional organ masses in the standard adult and the standard 25 g mouse. Time-dependent total-body activity was fit to an exponential function and the difference between the injected activity and the total-body activity was assumed to be excreted via the urine because activity concentrations in the liver and gastrointestinal tract were low at all timepoints studied.

Organ residence time was calculated by numerical integration using the trapezoidal rule and the rest-of-body. 18F residence times were calculated as the difference between the total-body residence time and the sum of the organ and urine residence times. The bladder contents residence time was estimated using the dynamic voiding model in the OLINDA/EXM 1.0 dosimetry software (Vanderbilt University, Nashville, TN, USA). Finally, the standard adult mean absorbed dose to organs (in µGy/MBq) and total effective dose (in µSv/MBq) were calculated using OLINDA/EXM 1.0 [14].

Human biodistribution

Patients

Data from patients with histopathologically proven prostate cancer who underwent a clinically indicated PET/CT with 18F-rhPSMA-7 or 18F-rhPSMA-7.3 between October 2017 and November 2018 were retrospectively analyzed. 18F-rhPSMA-7 PET/CT was performed in 47 patients (mean [range] age: 69.8 [52–80] years) with a mean injected activity of 324 (range, 236–424) MBq and mean acquisition time of 84 (range, 42–166) min. 18F-rhPSMA-7.3 PET/CT was performed in 33 patients (mean [range] age: 70.8 [57–85] years) with a mean injected activity of 345 (range, 235–420) MBq and mean acquisition time of 76 (range, 59–122) min. The mean prostate-specific antigen level at the time of imaging was 42.9 ng/mL (median range, 0–1459 ng/mL) for 18F-rhPSMA-7 and 20.0 ng/mL (range, 0–202 ng/mL) for 18F-rhPSMA-7.3, respectively. Patients received an injection of 20 mg of furosemide at the time of tracer application. A comparison of the disease stages and primary Gleason Scores of both cohorts are presented in Additional file 1: Table S5.

All patients gave written informed consent for the original procedure. All reported investigations were conducted in accordance with the Helsinki Declaration and with national regulations. This retrospective analysis was approved by the Local Ethics Committee (permits 290/18S and 99/19S) and the need for patient consent was waived. The administration of 18F-rhPSMA-7 and 18F-rhPSMA-7.3 was in accordance with The German Medicinal Products Act (AMG §13 2b) and the responsible regulatory body (Government of Oberbayern).

PET/CT imaging

All the PET/CT scans were obtained from the skull base to mid-thigh using a Biograph mCT Flow scanner (Siemens Medical Solutions, Erlangen, Germany). PET scanning was operated in 3D mode with an acquisition time of 1.1 mm/s in continuous table movement, and a diagnostic CT scan (240 mAs, 120 kV, 5 mm slice thickness) was acquired in the portal venous phase 80 s after the intravenous injection of an iodinated contrast agent (Imeron 400, Bracco Imaging Deutschland GmbH, Konstanz, Germany). Reconstruction of the PET images was performed based on iterative algorithms with an ordered-subsets expectation maximization (4 iterations, 8 subsets) followed by a post-reconstruction smoothing Gaussian filter (5 mm full width at one-half maximum).

Image analysis

For both quantitative and qualitative analyses PET datasets (non-Time-of-Flight/non-True X) were used. The maximum standardized uptake value (SUVmax) and the mean standardized uptake value (SUVmean) with an isocontour of 50% of the SUVmax were determined applying circular volumes of interest (VOIs) using OsiriX MD® 11.0.2 (Pixmeo SARL, Geneva, Switzerland).

The circular VOIs were placed over normal organs; parotid gland, submandibular gland, mediastinal aortic arch (blood pool), lungs, liver, spleen, pancreas, duodenum, kidneys, bladder, sacral promontory, and background (gluteus maximus muscle). Up to 3 lesions per patient were analyzed in decreasing order of SUVmax. Organ/tumour to background ratios (ratio-SUVmean, ratio-SUVmax) were calculated.

To evaluate overall image quality, non-specific blood pool activity and background uptake in bone/marrow was analysed using 3- or 4-point scales as previously described [7]. All the analyses were performed by a board-certified nuclear medicine physician.

Statistical analysis

Prior to analysis, the Kolmogorov–Smirnov test was used to assess the normality of the data distribution. The independent Student t-test was performed to compare
means between groups for the normal parameters. The Mann–Whitney U test was conducted for the non-normal parameters. The Chi-square test or the Fisher’s exact test was adopted to compare differences among groups for the analyses of ordinal variables. Data were expressed as mean ± standard deviation (SD) for continuous variables and frequencies (percentages, %) for categorical variables, respectively. All statistical analyses were performed using the IBM SPSS Statistics version 25 (IBM Inc. Armonk, NY, USA) and R version 3.5.2 (http://www.r-project.org). P values less than 0.05 were considered statistically significant.

Results
Preclinical biodistribution and dosimetry
Significant accumulation of radioactivity was observed (i.e. source organs) in the kidney, spleen, lung, liver and heart for both $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3. The activity distributed to individual organs is presented for the source organs and whole organs in Additional file 1: Table S1 and S2, respectively. The AUCs in the source organs are summarized in Table 1, and only results calculated from the AUCs with extrapolation and physical decay were used in the following analyses. Radioactivity distribution of both $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 was found to be the highest in the kidneys at most time-points. With respect to activity accumulation and clearance, a rapid clearance from blood and clearance to urine but relatively slow build-up in the kidneys was present for both $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3.

Extrapolating the preclinical dosimetry data to humans revealed that at 1 h and 3.5 h bladder voiding intervals, the total effective doses for humans are 12.2 and 12.8 µSv/MBq for $^{18}$F-rhPSMA-7, and 12.8 and 21.7 µSv/MBq for $^{18}$F-rhPSMA-7.3, respectively. Relative to the other organs, the kidneys exhibited particularly high uptake values of both rhPSMA ligands, but radiotracer retention in the urinary bladder was comparatively low. Moreover, the mean bladder SUV$_{\text{mean}}$, and ratio-SUV$_{\text{mean}}$ were significantly lower for $^{18}$F-rhPSMA-7 than for $^{18}$F-rhPSMA-7.3, respectively. Qualitative analyses of image quality revealed no significant differences between $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 PET (Additional file 1: Table S4).

Tumour uptake was analyzed in 89 lesions (26 primary tumours/local recurrences, 23 bone, 38 lymph node and 2 visceral metastases) and 63 lesions (14 primary tumours/local recurrences, 30 bone, 18 lymph node and 1 visceral metastases) for $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3, respectively. Mean tumour SUV$_{\text{mean}}$ (20.0 ± 20.2 for $^{18}$F-rhPSMA-7 vs. 32.5 ± 42.7 for $^{18}$F-rhPSMA-7.3) and mean ratio-SUV$_{\text{mean}}$ (36.0 ± 45.5 for $^{18}$F-rhPSMA-7 vs. 50.9 ± 68.7 for $^{18}$F-rhPSMA-7.3) showed a trend towards

| Table 1 | Time-integration of activity for accumulation in significant source organs (AUCs) |
|---------|---------------------------------|
| AUC (%IA/g) organ | Heart | Lung | Liver | Spleen | Kidney |
| $^{18}$F-rhPSMA-7 | No extrapolation | 0.17 ± 0.01 | 0.84 ± 0.04 | 0.78 ± 0.05 | 1.93 ± 0.13 | 6.39 ± 0.65 |
| | Extrapolation + physical decay | 0.18 ± 0.01 | 0.9 ± 0.04 | 0.87 ± 0.06 | 2.1 ± 0.13 | 10.12 ± 0.75 |
| $^{18}$F-rhPSMA-7.3 | No extrapolation | 0.29 ± 0.03 | 1.35 ± 0.12 | 1.25 ± 0.08 | 2.05 ± 0.2 | 8.99 ± 0.64 |
| | Extrapolation + physical decay | 0.3 ± 0.03 | 1.38 ± 0.12 | 1.33 ± 0.08 | 2.08 ± 0.2 | 10.8 ± 0.74 |

AUC: area under the curve; %IA: %injected activity. AUC is presented ± standard deviation

| Table 2 | Dosimetry results using 1 h and 3.5 h voiding interval |
|---------|---------------------------------|
| Voiding interval | $^{18}$F-rhPSMA-7 | $^{18}$F-rhPSMA-7.3 |
| Effective dose (µSv/MBq) | Effective dose (µSv/MBq) |
| 1 h | 12.2 | 12.8 |
| 3.5 h | 26.6 | 21.7 |

$^{18}$F-rhPSMA-7 (64.70 and 65.10 µGy/MBq at 1 h and 3.5 h, respectively; Additional file 1: Table S3).
higher tumour uptake values for $^{18}$F-rhPSMA-7.3 but without statistical significance ($p > 0.05$, Fig. 1, Table 3).

Figure 2 demonstrates the maximum intensity projection images of patients with normal biodistribution of $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3. Additional file 1: Figure S1 demonstrates the maximum intensity projection images and PET/CT fused images of two patients with early biochemical recurrence who have undergone $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 PET/CT, respectively.

**Discussion**

Here, we conducted a series of preclinical and human biodistribution and dosimetry studies to compare the profiles of two lead rhPSMA ligands for prostate cancer imaging. The results of the preclinical elements of this study indicate that the biodistribution and dosimetry profiles for both $^{18}$F-rhPSMA-7 and its single diastereoisomer form, $^{18}$F-rhPSMA-7.3, are favourable for prostate cancer imaging. The human clinical biodistribution results confirm and extend the preclinical data to indicate that while the profiles of $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 are similar, the significantly lower bladder uptake, and the trend towards higher uptake in tumours with $^{18}$F-rhPSMA-7.3 suggest that it is the more promising agent for further clinical translation.

The AUCs in the mouse dosimetry studies showed that $^{18}$F-rhPSMA-7.3 exhibited appropriate profiles for human study. Compared with $^{18}$F-rhPSMA-7, kidney uptakes of $^{18}$F-rhPSMA-7.3 were higher, but its accumulation speed was relatively slow. Thus, dosimetry studies of $^{18}$F-rhPSMA-7.3 were planned to be performed at a
late timepoint (300 min) to acknowledge this slow build-up in the kidneys. This kinetic profile could be helpful for PSMA ligand imaging. Since urinary excretion of the radiotracer is slow, excretion may not contribute to the kidney uptakes at early imaging timepoints, which in turn leads to lower bladder radioactivity levels and lower levels of background.

While direct conversion of preclinical dosimetry studies using mice into human data will not truly model the human profile, it is reasonable to assume that kinetic profiles are similar in humans. In our earlier work with $^{18}$F-rhPSMA-7, we recommended an early imaging timepoint (50–70 min) for $^{18}$F-rhPSMA-7 as lower tracer retention in the urinary bladder is an important feature for PSMA ligand PET imaging [7] and it is expected that PET/CT with $^{18}$F-rhPSMA-7.3 could also achieve good image quality at early imaging timepoints, especially given the significantly lower bladder SUV that we observe here.

The extrapolated effective doses for humans calculated from the preclinical dosimetry show estimated effective doses of both rhPSMA ligands that are comparable with those of other $^{18}$F-based PSMA ligands. The estimated effective doses using 1 h voiding interval were 12.2 µSv/MBq for $^{18}$F-rhPSMA-7 and 12.8 µSv/MBq for $^{18}$F-rhPSMA-7.3, respectively, leading to an effective dose of less than 5 mSv after injection of 370 MBq of either rhPSMA ligand. Radiation dosimetry studies revealed a mean effective dose of 19.9 µSv/MBq for $^{18}$F-DCFBC [4], 13.9 µSv/MBq for $^{18}$F-DCFPyL [5], and 22.0 µSv/MBq for $^{18}$F-PSMA-1007 [6]. $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 also provide favourable effective doses in comparison with $^{18}$F-FDG, which has a reported effective dose of 19.0 µSv/MBq [15]. In the present study the kidneys received among the highest doses with both rhPSMA ligands. This is in line with data previously reported for $^{18}$F-rhPSMA-7.3 in healthy volunteers [16]. Tolvanen et al. reported the kidneys to be one of the organs with the highest mean absorbed doses (172 µGy/MBq at a 3.5 h voiding window) [16]. All PSMA ligands share similar physiological distribution; organ absorbed doses are known to differ minimally among various PSMA ligands [6] and the data for $^{18}$F-rhPSMA-7.3 appear comparable with other agents.

Our clinical data demonstrate that, in humans, the normal biodistribution of $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 are similar, but with some slight, but notable differences that are relevant to prostate cancer imaging. Defining the extent of urinary excretion of novel PSMA ligands is imperative given that PSMA ligands that are mainly excreted via the urinary tract often show high radiotracer uptake in the bladder that can interfere with image interpretation in the prostate region [17, 18]. Our data show low relative bladder uptake with both rhPSMA ligands, but, of the two ligands, bladder uptake is significantly lower with $^{18}$F-rhPSMA-7.3 than $^{18}$F-rhPSMA-7. Moreover, while the tumour uptake of both rhPSMA ligands is higher than the kidney uptakes, facilitating easy localization of tumours with both rhPSMA ligands via PET/CT, there was a trend towards higher tumour SUV with $^{18}$F-rhPSMA-7.3. The qualitative PET/CT image interpretation analysis confirm the suitability of both agents for prostate imaging.

Some limitations to the present study should be acknowledged. First, direct conversion of preclinical dosimetry studies to humans may not truly reflect
human dosimetry, and thus, interpretation of the estimated effective doses reported here should be performed with caution. Second, our observations of low bladder retention of both ligands may be confounded by the application of furosemide at the time of tracer injection which is routinely done at our institution. It is known from $^{68}$Ga-PSMA-11 that this can substantially lower bladder retention due to forced bladder emptying prior to the PET scan. Third, we acknowledge a trend towards higher tumour SUV using $^{18}$F-rhPSMA-7.3 compared with $^{18}$F-rhPSMA-7. However, an intrather rather than an intra-patient comparison can be affected by several clinical variables (e.g. tumour stage, differences in PSMA-expression, prior treatments). Fourth, definitive conclusions about the uptake characteristics in tumors comparing both cohorts are limited as they base on different patient cohorts. Despite the patient cohorts are weighted for disease stage differences in the distribution of primary Gleason Scores and PSA at imaging have to be acknowledged.

**Conclusion**
Radiation dosimetry is favourable both for $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 with an estimated effective dose of less than 5 mSv, assuming a 1 h voiding interval after injection of 370 MBq of the radiotracer. Human biodistribution of $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 were similar to each other, but significantly lower bladder uptake and a trend towards higher uptake in tumour lesions was seen with $^{18}$F-rhPSMA-7.3.

**Abbreviations**
PSMA: Prostate-specific membrane antigen; rhPSMA: Radiohybrid PSMA; SCID: Severe combined immunodeficiency; AUC: Area under curve; %ID: Percentage of the injected dose; PET: Positron emission tomography; CT: Computed tomography; SUV$_{\text{max}}$: Maximum standardized uptake value; SUV$_{\text{mean}}$: Mean standardized uptake value; VOI: Volume of interest.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s13550-021-00872-w.

**Additional file 1**
**Supplementary Table 1.** Mean ± SD %ID/g for $^{18}$F-rhPSMA-7. **Supplementary Table 2.** Mean ± SD %ID/g for $^{18}$F-rhPSMA-7.3. **Supplementary Table 3.** Radiation dose estimates for $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 at 1h and 3.5h bladder voiding intervals. **Supplementary Table 4.** Comparisons of qualitative image parameters between $^{18}$F-rhPSMA-7 and $^{18}$F-rhPSMA-7.3 in humans. **Supplementary Table 5.** Clinical characteristics of patients who underwent Screening Table 1. Clinical characteristics of patients who underwent 18F-rhPSMA-7 (n = 47) and 18F-rhPSMA-7.3 (n = 33) PET/CT-rhPSMA-7 (n = 47) and Supplementary Table 5. Clinical characteristics of patients who underwent 18F-rhPSMA-7 (n = 47) and 18F-rhPSMA-7.3 (n = 33) PET/CT-rhPSMA-7 (n = 33) PET/CT. **Figure 1.** Two examples of patients with early biochemical recurrence (PSA<1 ng/ml) after radical prostatectomy who have undergone $^{18}$F-rhPSMA-7 (A) and $^{18}$F-rhPSMA-7.3 PET/CT.

**Acknowledgements**
None

**Authors’ contributions**
Design of the study: ME, KK, HJW, SN; preclinical experiments: NY, AW, HJW, SN, CD; retrospective clinical data analysis: SWO, MK, ME, KK; manuscript drafting: KK, ME, SWO; manuscript editing: KK, SWO, MK, AW, CD, MH, WW, HJW, ME, NY, SN. All authors commented on previous versions of the manuscript and read and approved the final manuscript.

**Funding**
Open Access funding enabled and organized by Projekt DEAL.

**Availability of data and materials**
Anonymised data are available from the Corresponding author on reasonable request.

**Declarations**

**Ethics approval**
The preclinical evaluation study was performed in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval #55.2-1-54-2532-216-2015). The retrospective analysis was approved by the Local Ethics Committee (permits 290/18S and 99/19S).

**Consent to participate**
Patient consent was waived by the local Ethics Committee (permits 290/18S and 99/19S) given the retrospective nature of the analysis.

**Consent for publication**
Patient consent was waived by the local Ethics Committee (permits 290/18S and 99/19S) given the retrospective nature of the analysis.

**Competing interests**
Patent application for rhPSMA (HJW, AW and ME). HJW and ME received funding from the SFB 824 (DFG Sonderforschungsbereich 824, Project B11) from the Deutsche Forschungsgemeinschaft, Bonn, Germany and Blue Earth Diagnostics Limited (licensee for rhPSMA) as part of an academic collaboration. HJW is founder, shareholder and advisor board member of Scintomics GmbH, Fuerstenfeldbruck, Germany. WW is a consultant for Blue Earth Diagnostics Limited. ME reports prior consulting activities for Blue Earth Diagnostics, Progenics Pharmaceuticals, Point Biopharma and Janssen Pharmaceuticals. No other potential conflicts of interest relevant to this article exist.

**Author details**
1 School of Medicine, Klinikum Rechts der Isar, Department of Nuclear Medicine, Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany. 2 Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul, Korea. 3 School of Medicine, Klinikum Rechts der Isar, Department of Diagnostic and Interventional Radiology, Technical University of Munich, Munich, Germany. 4 Chair for Pharmaceutical Radiopharmacy, TUM, Garching, Germany.

**Received: 2 July 2021 Accepted: 6 December 2021**
**Published online: 04 February 2022**

**References**
1. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61.
2. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.
3. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578–82.

4. Cho SY, Gage KL, Mease RC, Senthambizhevelavan S, Holt DP, Jeffrey-Kwantes AJ, et al. Biodistribution, tumor detection, and radiation dosimetry of [18F]-DCFABC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–91.

5. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate Cancer. Mol Imaging Biol. 2015;17:565–74.

6. Giesel FL, Hadashik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88.

7. Oh SW, Wurzer A, Teoh Et, Oh S, Langbein T, Kronke M, et al. Quantitative and qualitative analyses of biodistribution and PET image quality of novel radiohybrid PSMA, [18F]-rhPSMA-7, in patients with prostate cancer. J Nucl Med. 2019;61:702–9.

8. Eiber M, Kronke M, Wurzer A, Ulbrich L, Jooss L, Maurer T, et al. [18F]-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy. J Nucl Med. 2019;61:696–701.

9. Kronke M, Wurzer A, Schwamborn K, Ulbrich L, Jooss L, Maurer T, et al. Histologically-confirmed diagnostic efficacy of [18F]-rhPSMA-7 positron emission tomography for N-staging of patients with primary high risk prostate cancer. J Nucl Med. 2019;61:710–5.

10. Wurzer A, Parminger M, Konrad M, Beck R, Günther T, Feber V, et al. Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics. EJNMMI Res. 2020;10:149.

11. Wurzer A, DiCarlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, et al. Radiohybrid ligands: a novel tracer concept exemplified by [18F]- or [68Ga]-labeled rhPSMA-inhibitors. J Nucl Med. 2019;61:735–42.

12. Yuan J. Estimation of variance for AUC in animal studies. J Pharm Sci. 1993;82:761–3.

13. Kirschner AS, Ice RD, Beierwaltes WH. Radiation dosimetry of 131I–19–iodocholestrol. J Nucl Med. 1973;14:713–7.

14. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.

15. International Commission on Radiological Protection. ICRP publication 106, addendum 3 to ICRP publication 53: radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon; 2007.

16. Tolvanen T, Kallkoski KK, Malaspina S, Kuismia A, Lahdenpohja S, Postema Et, et al. Safety, biodistribution and radiation dosimetry of [18F]-rhPSMA-7 in healthy adult volunteers. J Nucl Med. 2020. https://doi.org/10.2967/jnumed.120.252114.

17. Heusser T, Mann P, Rank CM, Schafer M, Dimitrakopoulou-Strauss A, Schlemmer HP, et al. Investigation of the halo-artefact in [68Ga]-PSMA-11PET/MRI. PLoS ONE. 2017;12:e0183329.

18. Fendler WP, Eiber M, Reheshiti M, Bomanji J, Ceci F, Cho S, et al. [68Ga-PSMA PET/CT]. Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.